<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-26632" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Paraneoplastic Limbic Encephalitis</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Altabakhi</surname>
            <given-names>Ibrahim W.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Babiker</surname>
            <given-names>Hani M.</given-names>
          </name>
          <aff>University of Arizona Cancer Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Lui</surname>
            <given-names>Forshing</given-names>
          </name>
          <aff>CA Northstate Uni, College of Med</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ibrahim Altabakhi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hani Babiker declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Forshing Lui declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>12</day>
          <month>2</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-26632.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Paraneoplastic limbic encephalitis is thought to be caused by an onconeural antibody to cancer that cross-reacts with self-antigen in the neurons and muscles. It is a rare paraneoplastic syndrome that affects the limbic structures of the brain, especially the medial temporal lobes. It may present with cognitive dysfunction, change in personality, seizure, irritability, hallucinations, disorientation, limbic paresis, disruption of consciousness, and short-term memory loss. This activity reviews the evaluation and treatment of paraneoplastic limbic encephalitis and highlights the role of the interprofessional team in diagnosing and managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Differentiate between paraneoplastic LE and other neurological or psychiatric disorders through a comprehensive evaluation and exclusion process.</p></list-item><list-item><p>Implement a standardized diagnostic approach, including thorough neurological examinations and appropriate laboratory and imaging tests, to confirm or rule out paraneoplastic LE.</p></list-item><list-item><p>Apply evidence-based treatments for paraneoplastic LE, including tumor management and immunosuppressive therapies, considering individual patient characteristics and preferences.</p></list-item><list-item><p>Collaborate with a multidisciplinary healthcare team, including oncologists, neurologists, and mental health professionals, to ensure comprehensive care.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26632&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26632">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-26632.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Paraneoplastic syndrome is a rare immune-mediated complication that&#x000a0;arises as a remote effect of cancer, often occurring covertly.<xref ref-type="bibr" rid="article-26632.r1">[1]</xref>&#x000a0;This syndrome can manifest in various clinical presentations, including&#x000a0;encephalitis, Lambert-Eaton myasthenic syndrome,<xref ref-type="bibr" rid="article-26632.r2">[2]</xref>&#x000a0;typical abdominal symptoms associated with neuroblastoma such as severe constipation and chronic flatulence,<xref ref-type="bibr" rid="article-26632.r3">[3]</xref>&#x000a0;myelopathies,<xref ref-type="bibr" rid="article-26632.r4">[4]</xref>&#x000a0;movement disorders,<xref ref-type="bibr" rid="article-26632.r5">[5]</xref>&#x000a0;new-onset hyperglycemia,<xref ref-type="bibr" rid="article-26632.r6">[6]</xref>&#x000a0;intrahepatic cholestasis,<xref ref-type="bibr" rid="article-26632.r7">[7]</xref>&#x000a0;and various endocrine symptoms&#x000a0;involving corticotropin-releasing hormone, adrenocorticotropic hormone, antidiuretic hormone, among others.<xref ref-type="bibr" rid="article-26632.r8">[8]</xref><xref ref-type="bibr" rid="article-26632.r9">[9]</xref></p>
        <p>Paraneoplastic limbic encephalitis (LE) is a specific paraneoplastic syndrome&#x000a0;characterized by inflammation and&#x000a0;injury to the limbic structures, resulting in specific neuropsychiatric syndromes. Common clinical&#x000a0;presentations include memory impairment, psychosis, mood and behavioral disturbances, cognitive decline, abnormal movements,&#x000a0;altered levels of consciousness, dysautonomia, and seizures. Amygdala involvement may cause emotional disturbances and aggressive behavior, while hypothalamic involvement can disrupt&#x000a0;appetite and libido.</p>
        <p>Concerning&#x000a0;the pathogenesis of paraneoplastic LE, autoantibodies fall into 2&#x000a0;primary categories. The first group targets&#x000a0;cell-surface or synaptic antigens, provoking pathogenic responses&#x000a0;that trigger antibody and complement-mediated immune damage. The second group&#x000a0;targets intracellular antigens,&#x000a0;specifically&#x000a0;the classical onconeural antigens; these antibodies do not directly induce pathogenesis.&#x000a0;Instead, the immunological injury is&#x000a0;predominantly cell-mediated cytotoxicity. This second group is also more&#x000a0;frequently associated with paraneoplastic syndromes,&#x000a0;whereas antibodies directed against cell surface and synaptic antigens are often not paraneoplastic.<xref ref-type="bibr" rid="article-26632.r10">[10]</xref></p>
        <p>The best&#x000a0;approach for treating&#x000a0;paraneoplastic LE involves addressing the&#x000a0;underlying cancer if present. Repeated surveillance to detect any potential underlying cancer is indicated when no underlying cancer is identified, and immunotherapy can be a beneficial strategy for managing the syndrome.</p>
      </sec>
      <sec id="article-26632.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of paraneoplastic LE is&#x000a0;usually an underlying cancer. Antibodies&#x000a0;targeting intracellular antigens are more&#x000a0;frequently linked to&#x000a0;an underlying malignancy than antibodies directed against cell surface and synaptic antigens.&#x000a0;Certain types of&#x000a0;cancer are more&#x000a0;prone to be associated with paraneoplastic LE,&#x000a0;with&#x000a0;small cell lung cancer (SCLC) being a notable example.</p>
        <p>The more common&#x000a0;antigens&#x000a0;associated with paraneoplastic LE and underlying&#x000a0;malignancies are listed as follows (see <bold>Table.&#x000a0;</bold>Common&#x000a0;Antigens&#x000a0;Involved in&#x000a0;Paraneoplastic LE):<xref ref-type="bibr" rid="article-26632.r10">[10]</xref></p>
        <table-wrap id="article-26632.table0" position="float" orientation="portrait">
          <caption>
            <title>Table.&#x000a0;Common&#x000a0;Antigens Involved&#x000a0;in Paraneoplastic LE</title>
          </caption>
          <table style="height: 550px;" border="1" cellspacing="1" cellpadding="20">
            <tbody>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">
<bold>Antigen</bold>
</td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">
<bold>Cancer Frequency</bold>
</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">
<bold>Underlying Cancer</bold>
</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">HU&#x000a0;<xref ref-type="bibr" rid="article-26632.r2">[2]</xref></td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">90</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">SCLC</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">Ma-1/2&#x000a0;<xref ref-type="bibr" rid="article-26632.r11">[11]</xref></td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">90</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">Testicular tumor, non-small cell lung cancer (NSCLC)</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">Amphiphysin</td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">90</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">SCLC, breast cancer</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">CRMP5 (collapsin response mediator protein 5</td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">90</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">SCLC, thymoma</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">GAD (glutamic acid decarboxylase)&#x000a0;<xref ref-type="bibr" rid="article-26632.r11">[11]</xref></td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">25</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">SCLC, thymoma</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">LGI1 (leucine-rich, glioma inactivated)</td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">10</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">Multiple cancer types</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">CASPR2 (contactin-associated protein-like 2)</td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">20</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">Thymoma</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">NMDAR (N-methyl-D-aspartate receptor)&#x000a0;<xref ref-type="bibr" rid="article-26632.r12">[12]</xref></td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">40</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">Ovarian teratoma, testicuar cancer</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">GABABR (gamma aminobutyric acid B receptor)&#x000a0;<xref ref-type="bibr" rid="article-26632.r2">[2]</xref></td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">&#x000a0;50</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">&#x000a0;SCLC</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">mGluR5 (metabotropic glutamate receptor subtype 5)&#x000a0;<xref ref-type="bibr" rid="article-26632.r13">[13]</xref></td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">50</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">Hodgkins lymphoma</td>
              </tr>
              <tr>
                <td style="width: 233.056px;" rowspan="1" colspan="1">AMPAR (&#x003b1;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor)</td>
                <td style="width: 233.056px;" rowspan="1" colspan="1">60</td>
                <td style="width: 233.067px;" rowspan="1" colspan="1">
<p>SCLC, thymoma</p>
</td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
        <p>Antibodies to specific antigens, as&#x000a0;detailed in the&#x000a0;table above (see <bold>Table.</bold> Common Antigens Involved in Paraneoplastic LE), have been detected in many patients with paraneoplastic LE. However, these markers may be absent in some individuals.<xref ref-type="bibr" rid="article-26632.r14">[14]</xref>. Additionally, paraneoplastic LE&#x000a0;can&#x000a0;be&#x000a0;associated with solid tumors, whether they are primary or metastatic, and can occur in both occult and gross cancers<xref ref-type="bibr" rid="article-26632.r1">[1]</xref>. In males, particularly around 40,&#x000a0;testicular tumors&#x000a0;represent the most commonly identified causes. However,&#x000a0;overall, underlying lung cancer is the most prevalent cause of paraneoplastic LE.&#x000a0;</p>
        <p>Not all cases of LE are necessarily paraneoplastic. This condition can also manifest in individuals with other autoimmune diseases such as Type 1 diabetes, systemic sclerosis, or infections.<xref ref-type="bibr" rid="article-26632.r15">[15]</xref></p>
      </sec>
      <sec id="article-26632.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Autoimmune encephalitis is increasingly prevalent.<xref ref-type="bibr" rid="article-26632.r15">[15]</xref><xref ref-type="bibr" rid="article-26632.r16">[16]</xref>&#x000a0;Among its&#x000a0;subtypes, paraneoplastic LE, though rare, should be considered&#x000a0;a potential cause of altered mental status in young individuals, including children. This neurological paraneoplastic syndrome occurs in less than 1 per 10,000 patients. Notably, 50% of affected patients&#x000a0;may have underlying lung cancer, 20%&#x000a0;may have underlying testicular tumors,&#x000a0;and 8%&#x000a0;may have breast cancer diagnosis.<xref ref-type="bibr" rid="article-26632.r14">[14]</xref><xref ref-type="bibr" rid="article-26632.r17">[17]</xref>&#x000a0;</p>
        <p>The onset of paraneoplastic LE may occur at any age, depending on the specific underlying cancer. SCLC tends to be more common in older individuals, while testicular cancer is more prevalent in younger men.&#x000a0;</p>
      </sec>
      <sec id="article-26632.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Paraneoplastic LE is&#x000a0;believed to be&#x000a0;triggered by onconeural antibodies&#x000a0;produced in response to&#x000a0;cancer, which can cross-react with self-antigens in neurons and muscles.<xref ref-type="bibr" rid="article-26632.r1">[1]</xref>&#x000a0;While these antibodies&#x000a0;contribute&#x000a0;to this paraneoplastic syndrome, their absence does not exclude the syndrome. Therefore,&#x000a0;additional&#x000a0;research is required to elucidate the precise underlying mechanism of this condition.<xref ref-type="bibr" rid="article-26632.r1">[1]</xref><xref ref-type="bibr" rid="article-26632.r17">[17]</xref></p>
        <p>Classical paraneoplastic LE is more commonly associated with antibodies targeting intracellular antigens such as anti-Hu, Yo, Ri, Ma2, CRMP5, and amphiphysin. This group of LE is most widely associated with underlying cancer or real paraneoplastic.<xref ref-type="bibr" rid="article-26632.r18">[18]</xref></p>
        <p>In this form of LE, the pathological process is primarily mediated by a predominant T-cell mechanism, as evidenced by cytotoxic T cells in pathological specimens. The antibodies are not directly pathogenic but are markers for concurrent cytotoxic T-cell-mediated autoimmunity. Neuronal tissues share similar antigenicity with intracellular tumor antigens, contributing to neurological manifestations.<xref ref-type="bibr" rid="article-26632.r19">[19]</xref></p>
        <p>The second&#x000a0;category&#x000a0;of paraneoplastic LE is&#x000a0;characterized&#x000a0;by antibodies&#x000a0;targeting cell-surface or synaptic antigens. This group includes antibodies against NMDAR, LGI1, CASPR2, and other receptors. The&#x000a0;pathogenic&#x000a0;mechanism involves an antibody or B-cell-mediated autoimmune encephalitis.<xref ref-type="bibr" rid="article-26632.r19">[19]</xref></p>
        <p>This&#x000a0;category&#x000a0;of LE is less commonly associated with a paraneoplastic origin, and many patients with this autoimmune encephalitis do not have any underlying cancer. Typically, individuals affected by these types of LE tend to be younger. In anti-LGI1 and CASPR2 LE cases, an underlying cancer is associated with less than 20% of cases.<xref ref-type="bibr" rid="article-26632.r18">[18]</xref></p>
      </sec>
      <sec id="article-26632.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>An autopsy&#x000a0;of a patient with paraneoplastic LE revealed multiple areas of micro-softening within the cerebral cortex. These areas were distributed in the limbic and nonlimbic regions&#x000a0;and were accompanied by&#x000a0;lymphocytic infiltration in the intraparenchymal vessels.<xref ref-type="bibr" rid="article-26632.r20">[20]</xref>&#x000a0;Additionally, the autopsy&#x000a0;findings&#x000a0;included evidence of&#x000a0;T-cell&#x02014;dominated inflammation, neural loss, and microglial activation.<xref ref-type="bibr" rid="article-26632.r21">[21]</xref></p>
      </sec>
      <sec id="article-26632.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>The clinical features of LE, including the paraneoplastic subtype, exhibit significant variability, primarily&#x000a0;dependent upon the&#x000a0;specific&#x000a0;antibodies involved and the&#x000a0;affected brain regions in the autoimmune process.&#x000a0;The onset of LE is typically acute or subacute, marked by the rapid&#x000a0;development of diverse neuropsychiatric and neurological symptoms.&#x000a0;</p>
        <p>Notable clinical features that&#x000a0;warrant&#x000a0;particular attention in the patient's medical history encompass&#x000a0;the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Emerging psychiatric symptoms, such as new-onset psychosis, should be carefully assessed for associated features such as personality changes,&#x000a0;depressive or manic episodes, delusions, hallucinations, or catatonia. Patients presenting with these symptoms are frequently misdiagnosed as having primary psychiatric conditions, underscoring the importance of accurately distinguishing their underlying medical condition.&#x000a0;This&#x000a0;differentiation is particularly vital for patients with anti-NMDA LE.<xref ref-type="bibr" rid="article-26632.r22">[22]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>New onset seizures, especially medically refractory seizures, should be noted, as they often reflect the involvement of the medial temporal lobe, which is recognized as the most epileptogenic region of the brain.&#x000a0;Specific types of LE may exhibit distinct epileptic semiology and EEG patterns. For instance, faciobrachial dystonic seizures highly indicate&#x000a0;anti-LGI1 encephalitis, while the extreme delta brush EEG pattern is often&#x000a0;observed in cases of anti-NMDAR LE.<xref ref-type="bibr" rid="article-26632.r23">[23]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Movement disorders, mainly when they manifest young, should be carefully evaluated. Orofacial dyskinesia is&#x000a0;a prevalent feature among patients with anti-NMDAR LE. Additionally, Morvan syndrome is&#x000a0;characteristic of individuals with&#x000a0;anti-CASPR2 LE.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cognitive impairment stands out as the most consistently observed characteristic in cases of paraneoplastic LE.<xref ref-type="bibr" rid="article-26632.r24">[24]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Sleep disturbances are a frequently encountered but often underestimated aspect of this condition. Common sleep disorders associated with LE include REM sleep behavioral disorders, insomnia, periodic movements&#x000a0;during sleep, hypersomnia, and fragmented sleep.<xref ref-type="bibr" rid="article-26632.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>LE is often diagnosed before the&#x000a0;discovery of the underlying cancer.<xref ref-type="bibr" rid="article-26632.r11">[11]</xref>.&#x000a0;Occasionally,&#x000a0;it may&#x000a0;be mistaken for&#x000a0;complications of chemotherapy. Therefore, when&#x000a0;suspected of this syndrome, it is essential to conduct a comprehensive medical&#x000a0;history and physical examination to identify the underlying cancer. Assessing cognitive&#x000a0;function can be achieved&#x000a0;through tools such as the Mini-Mental State Examination, clock test, or evaluation of instrumental&#x000a0;activities&#x000a0;of daily living.<xref ref-type="bibr" rid="article-26632.r26">[26]</xref>&#x000a0;Furthermore, this syndrome may be a part of&#x000a0;a&#x000a0;broader&#x000a0;condition in which the inflammatory process involves the limbic system, brain stem, and spinal cord.<xref ref-type="bibr" rid="article-26632.r27">[27]</xref></p>
      </sec>
      <sec id="article-26632.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Patients suspected of having paraneoplastic LE should undergo the following comprehensive diagnostic tests:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Blood test:</bold> Check for monoclonal antibodies, including anti-Hu, anti-Ta, anti-Ma, anti-GABA B receptor, and anti-NMDA receptor antibodies. However, note that the absence of these antibodies does not&#x000a0;definitively&#x000a0;exclude the disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>MRI:</bold>&#x000a0;T2-weighted images and fluid-attenuated inversion recovery sequences can provide&#x000a0;supportive evidence for&#x000a0;the diagnosis.<xref ref-type="bibr" rid="article-26632.r12">[12]</xref>&#x000a0;Hyperintense signals may be revealed in various brain regions, including the temporal lobe, hippocampal areas, insula, amygdala, or cingulate gyrus. It is important to note that MRI findings may sometimes appear later than the initial neurological symptoms of the syndrome.<xref ref-type="bibr" rid="article-26632.r28">[28]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Lumbar puncture:</bold>&#x000a0;Ideally, lumbar puncture results should be&#x000a0;negative for malignant cells or infection. However, they may indicate pleocytosis,&#x000a0;elevated&#x000a0;protein levels, increased&#x000a0;immunoglobulin synthesis, and oligoclonal bands.<xref ref-type="bibr" rid="article-26632.r27">[27]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Electroencephalography (EEG):</bold>&#x000a0;EEG will frequently&#x000a0;show sharp and slow waves.<xref ref-type="bibr" rid="article-26632.r27">[27]</xref></p>
          </list-item>
        </list>
        <p>Additional tests, such as PET-CT scans, can also be conducted. These scans help detect abnormal metabolic activities within the limbic system.</p>
        <p>Diagnosing paraneoplastic LE can be challenging and is typically based on exclusion because clinical markers are often absent. In a study involving 1047 patients, the following 4 criteria were utilized to establish a diagnosis:</p>
        <list list-type="order">
          <list-item>
            <p>The clinical presentation must align with the syndrome, encompassing its characteristic symptoms and signs.</p>
          </list-item>
          <list-item>
            <p>An interval of less than 4 years should exist between the onset of neurological symptoms or signs and the diagnosis of the associated tumor.</p>
          </list-item>
          <list-item>
            <p>Other neuro-oncological complications must be excluded as potential causes.</p>
          </list-item>
          <list-item>
            <p>Additionally, at&#x000a0;least&#x000a0;1 of the following criteria should be met:
<list list-type="order"><list-item><p>CSF analysis reveals inflammatory changes but negative cytology.</p></list-item><list-item><p>MRI imaging&#x000a0;demonstrates abnormalities in the temporal lobe.</p></list-item><list-item><p>EEG findings&#x000a0;indicate epileptic activities localized in the temporal lobe.</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Not all&#x000a0;patients will&#x000a0;meet these specific criteria. In some cases, the diagnosis of paraneoplastic LE can also be confirmed through neuropathological examination.<xref ref-type="bibr" rid="article-26632.r14">[14]</xref></p>
        <p>Additional diagnostic criteria, such as the Graus and Saiz criteria, can also be employed to aid in diagnosing paraneoplastic LE. These criteria encompass:</p>
        <list list-type="bullet">
          <list-item>
            <p>Subacute onset of seizure or confusion (occurring in &#x0003c;12 weeks).</p>
          </list-item>
          <list-item>
            <p>Evidence of neuropathological or radiological involvement of the limbic system.&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Exclusion of other potential causes.</p>
          </list-item>
          <list-item>
            <p>Diagnosis of the associated&#x000a0;tumor within 5 years of diagnosing the syndrome.<xref ref-type="bibr" rid="article-26632.r17">[17]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26632.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Managing the underlying tumor is considered the primary approach to address paraneoplastic LE, leading to gradual improvements&#x000a0;in the syndrome's signs and symptoms,&#x000a0;even if&#x000a0;radiological signs persist. This management can be achieved through chemotherapy or&#x000a0;surgical&#x000a0;tumor removal, and it is generally regarded as the first-line treatment option.<xref ref-type="bibr" rid="article-26632.r12">[12]</xref><xref ref-type="bibr" rid="article-26632.r14">[14]</xref><xref ref-type="bibr" rid="article-26632.r29">[29]</xref>&#x000a0;</p>
        <p>Along with supportive care, other available therapeutic options include high doses of corticosteroids, plasma exchange, high-dose immunoglobulin, and immunosuppressive drugs like azithromycin and rituximab.<xref ref-type="bibr" rid="article-26632.r11">[11]</xref>&#x000a0;Bortezomib may be considered in cases associated with anti-NMDA receptors,&#x000a0;particularly when dealing with refractory&#x000a0;cases.<xref ref-type="bibr" rid="article-26632.r1">[1]</xref><xref ref-type="bibr" rid="article-26632.r17">[17]</xref><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="lt;a href=">[24]</ext-link><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmid" xlink:href="29667271">[30]</ext-link><xref ref-type="bibr" rid="article-26632.r30">[30]</xref><xref ref-type="bibr" rid="article-26632.r31">[31]</xref></p>
        <p>A combination of these drugs may be applied in certain cases.<xref ref-type="bibr" rid="article-26632.r17">[17]</xref><xref ref-type="bibr" rid="article-26632.r31">[31]</xref><xref ref-type="bibr" rid="article-26632.r32">[32]</xref>&#x000a0;However, research indicates&#x000a0;that&#x000a0;addressing the underlying tumor&#x000a0;tends&#x000a0;to be more effective than other therapeutic options,&#x000a0;as steroids may&#x000a0;occasionally be ineffective.<xref ref-type="bibr" rid="article-26632.r14">[14]</xref></p>
        <p>The replacement fluid in plasma exchange may&#x000a0;consist of human albumin or fresh frozen plasma. However, it is important to be aware of potential complications, including hypotension, allergic reactions, mild anemia, hypocalcemia, and catheter placement complications.<xref ref-type="bibr" rid="article-26632.r31">[31]</xref><xref ref-type="bibr" rid="article-26632.r33">[33]</xref><xref ref-type="bibr" rid="article-26632.r34">[34]</xref></p>
      </sec>
      <sec id="article-26632.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Before establishing a diagnosis of paraneoplastic limbic encephalitis, it is essential to rule out several significant differential diagnoses, including:<xref ref-type="bibr" rid="article-26632.r35">[35]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Infectious encephalitis&#x000a0;</bold>encompasses&#x000a0;viral infections (specifically herpes simplex), fungal infections, and tuberculous infections.<xref ref-type="bibr" rid="article-26632.r36">[36]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Systemic autoimmune diseases&#x000a0;</bold>such as systemic lupus and Behcet disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Toxic-metabolic causes&#x000a0;</bold>include substance abuse and Wernicke encephalopathy.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Rapidly progressive neurodegenerative disorders&#x000a0;</bold>such as Creutzfeld-Jakob disease.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neoplastic diseases</bold> with particular consideration given to&#x000a0;lymphoma.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Neurological complications&#x000a0;</bold>stemming&#x000a0;from chemotherapy or other relevant medical diseases.<xref ref-type="bibr" rid="article-26632.r37">[37]</xref><xref ref-type="bibr" rid="article-26632.r38">[38]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26632.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Timely&#x000a0;diagnosis and treatment of malignant tumors are pivotal&#x000a0;in enhancing the prognosis and expediting clinical recovery.<xref ref-type="bibr" rid="article-26632.r39">[39]</xref>&#x000a0;However, different autoantibodies are associated with varying prognostic outcomes as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with anti-Hu antibodies, especially those with multifocal neurological symptoms, tend to have a poorer prognosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with anti-Ta antibodies are also often associated with a poor prognosis.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Individuals without detectable autoantibodies in their blood generally exhibit a more favorable prognosis.<xref ref-type="bibr" rid="article-26632.r14">[14]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Patients with anti-GABA B receptor antibodies may respond better to immunosuppressant drugs than patients with anti-Hu antibodies.<xref ref-type="bibr" rid="article-26632.r39">[39]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-26632.s12" sec-type="Complications">
        <title>Complications</title>
        <p>Achieving a full recovery of higher cerebral function in autoimmune encephalitis can sometimes be challenging. However, symptoms are often improved in the paraneoplastic subtype of autoimmune encephalitis after effectively managing the associated tumor through medical or surgical interventions.<xref ref-type="bibr" rid="article-26632.r40">[40]</xref><xref ref-type="bibr" rid="article-26632.r41">[41]</xref></p>
      </sec>
      <sec id="article-26632.s13" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Following&#x000a0;discharge from the hospital, rehabilitation may be necessary for an extended period, with certain patients requiring several months of ongoing rehabilitation.<xref ref-type="bibr" rid="article-26632.r15">[15]</xref><xref ref-type="bibr" rid="article-26632.r42">[42]</xref></p>
      </sec>
      <sec id="article-26632.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Upon establishing the diagnosis of paraneoplastic LE, consultations with medical specialists should be arranged based on the patient's medical history and physical examination findings. These consultations may involve gynecologic oncologists, urological oncologists, pulmonologists, or other relevant physicians from&#x000a0;various specialties.<xref ref-type="bibr" rid="article-26632.r43">[43]</xref></p>
      </sec>
      <sec id="article-26632.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patient education for paraneoplastic limbic encephalitis should focus on several key aspects to help individuals understand the condition and its management. LE often presents with frequent behavioral and neuropsychiatric symptoms, which can be misleading and lead to its misdiagnosis as a psychiatric issue.&#x000a0;This misdiagnosis can result in delayed&#x000a0;treatment and a worsened&#x000a0;prognosis. Consequently, patients and clinicians must maintain a high index of suspicion&#x000a0;for this&#x000a0;significant diagnosis if there is any change in neurological or psychiatric health.</p>
        <p>Furthermore, patient education plays a pivotal role in raising awareness about activities that could potentially increase the risk of malignancy, emphasizing avoiding risk factors like smoking. This proactive approach can contribute to early detection and improved outcomes.</p>
      </sec>
      <sec id="article-26632.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Enhancing healthcare team outcomes for paraneoplastic&#x000a0;LE involves the collaborative efforts of an interprofessional healthcare team comprising various specialists, healthcare providers, and support staff. This approach is essential for accurate diagnosis, effective treatment, and improved patient outcomes. Each member of the healthcare team contributes to achieving better outcomes as outlined below:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Primary Care Physician:</bold> The patient's primary care physician often plays a crucial role in recognizing early symptoms and referring the patient to specialists for further evaluation and diagnosis.</p>
          </list-item>
          <list-item>
            <p><bold>Neurologist:</bold> Neurologists are central to the diagnosis and management of LE. They conduct neurological assessments, order relevant tests, and guide treatment options.</p>
          </list-item>
          <list-item>
            <p><bold>Oncologist:</bold> Oncologists are responsible for diagnosing and treating the underlying malignancy. They collaborate with the neurologist to determine the best approach, which may include surgery, chemotherapy, or radiation therapy.</p>
          </list-item>
          <list-item>
            <p><bold>Radiologist:</bold> Radiologists interpret imaging studies, such as MRI scans, to identify abnormalities in the brain or surrounding structures, aiding in diagnosis and treatment planning.</p>
          </list-item>
          <list-item>
            <p><bold>Pathologist:</bold> Pathologists analyze tissue samples to confirm the presence of malignancy and assess its characteristics, which informs treatment decisions.</p>
          </list-item>
          <list-item>
            <p><bold>Neuropsychiatrist:</bold> As LE often presents with psychiatric symptoms, neuropsychiatrists are essential in evaluating and managing the behavioral and psychological aspects of the condition.</p>
          </list-item>
          <list-item>
            <p><bold>Clinical Nurse Specialist/Nurse Practitioner:</bold> These healthcare professionals provide ongoing patient care, administer treatments, monitor for side effects, and educate patients and their families about the condition and treatment.</p>
          </list-item>
          <list-item>
            <p><bold>Physical and Occupational Therapists:</bold> Rehabilitation specialists work to improve the patient's physical and cognitive function through tailored exercise and therapy programs.</p>
          </list-item>
          <list-item>
            <p><bold>Psychologists and Counselors:</bold> Mental health professionals offer psychological support and counseling to help patients cope with the emotional and psychological challenges associated with the diagnosis and treatment.</p>
          </list-item>
          <list-item>
            <p><bold>Pharmacists:</bold> Pharmacists ensure the safe and appropriate use of medications, including immunosuppressive drugs and symptom management medications.</p>
          </list-item>
          <list-item>
            <p><bold>Caregivers and Family Members:</bold> The patient's caregivers and family members are integral to the healthcare team, offering support, assisting with daily care, and participating in decision-making.</p>
          </list-item>
        </list>
        <p>Effective communication and collaboration among team members are essential. Regular case conferences, multidisciplinary meetings, and shared electronic medical records help ensure that all aspects of patient care are coordinated. By fostering collaboration among these healthcare professionals, patients with paraneoplastic limbic encephalitis can receive comprehensive and coordinated care, leading to earlier diagnosis, effective treatment, improved symptom management, and better overall outcomes.</p>
      </sec>
      <sec id="article-26632.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=26632&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=26632">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/paraneoplastic-limbic-encephalitis/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=26632">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/26632/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=26632">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-26632.s18">
        <title>References</title>
        <ref id="article-26632.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inuzuka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Paraneoplastic neurological syndrome--definition and history].</article-title>
            <source>Brain Nerve</source>
            <year>2010</year>
            <month>Apr</month>
            <volume>62</volume>
            <issue>4</issue>
            <fpage>301</fpage>
            <page-range>301-8</page-range>
            <pub-id pub-id-type="pmid">20420169</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Titulaer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic syndromes and autoimmune encephalitis: Five new things.</article-title>
            <source>Neurol Clin Pract</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>215</fpage>
            <page-range>215-223</page-range>
            <pub-id pub-id-type="pmid">23634368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Czkwianianc</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Zalewska-Szewczyk</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kobos</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Socha-Banasiak</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Janczar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Prymus-Kasi&#x00144;ska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kazanek-Zasada</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>M&#x00142;ynarski</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Uncommon reasons of the digestive tract-related paraneoplastic syndromes in children with neuroblastic tumors: three case reports.</article-title>
            <source>Contemp Oncol (Pozn)</source>
            <year>2018</year>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-46</page-range>
            <pub-id pub-id-type="pmid">29692663</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ranjan</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Neoplastic Myelopathies.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2, Spinal Cord Disorders</issue>
            <fpage>474</fpage>
            <page-range>474-496</page-range>
            <pub-id pub-id-type="pmid">29613896</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pop&#x00142;awska-Domaszewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Florczak-Wyspia&#x00144;ska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kozubski</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Michalak</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic movement disorders.</article-title>
            <source>Rev Neurosci</source>
            <year>2018</year>
            <month>Sep</month>
            <day>25</day>
            <volume>29</volume>
            <issue>7</issue>
            <fpage>745</fpage>
            <page-range>745-755</page-range>
            <pub-id pub-id-type="pmid">29561731</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gapp</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Anwar</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Parekh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>New onset hyperglycemia attributed to renal cell carcinoma.</article-title>
            <source>Intractable Rare Dis Res</source>
            <year>2018</year>
            <month>May</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>134</fpage>
            <page-range>134-137</page-range>
            <pub-id pub-id-type="pmid">29862157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhangoo</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Botta</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Thorson</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kosty</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Reversible intrahepatic cholestasis in metastatic prostate cancer: An uncommon paraneoplastic syndrome.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>8</volume>
            <issue>4</issue>
            <fpage>609</fpage>
            <page-range>609-612</page-range>
            <pub-id pub-id-type="pmid">29541472</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richa</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Saad</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Halabi</surname>
                <given-names>GH</given-names>
              </name>
              <name>
                <surname>Gharios</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Nasr</surname>
                <given-names>FL</given-names>
              </name>
              <name>
                <surname>Merheb</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Case-series of paraneoplastic Cushing syndrome in small-cell lung cancer.</article-title>
            <source>Endocrinol Diabetes Metab Case Rep</source>
            <year>2018</year>
            <volume>2018</volume>
            <pub-id pub-id-type="pmid">29535866</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reisch</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Reincke</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>[Endocrine paraneoplastic syndromes].</article-title>
            <source>Internist (Berl)</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>59</volume>
            <issue>2</issue>
            <fpage>125</fpage>
            <page-range>125-133</page-range>
            <pub-id pub-id-type="pmid">29387897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ding</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Dongas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ding</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Limbic Encephalitis: A Review of Clinicoradiological Features and the Challenges of Diagnosis.</article-title>
            <source>Cureus</source>
            <year>2021</year>
            <month>Aug</month>
            <volume>13</volume>
            <issue>8</issue>
            <fpage>e17529</fpage>
            <pub-id pub-id-type="pmid">34603897</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kubota</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tajima</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Narukawa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamazato</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fukaura</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Takahashi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tanaka</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shimizu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>[Anti-Ma2, anti-NMDA-receptor and anti-GluR&#x003b5;2 limbic encephalitis with testicular seminoma: short-term memory disturbance].</article-title>
            <source>Rinsho Shinkeigaku</source>
            <year>2012</year>
            <volume>52</volume>
            <issue>9</issue>
            <fpage>666</fpage>
            <page-range>666-71</page-range>
            <pub-id pub-id-type="pmid">22989902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inoue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanno</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Moriya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nakamura</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Matsumura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Suzuki</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A Case of Paraneoplastic Limbic Encephalitis in a Patient with Invasive Thymoma with Anti-Glutamate Receptor Antibody-Positive Cerebrospinal Fluid: A Case Report.</article-title>
            <source>Ann Thorac Cardiovasc Surg</source>
            <year>2018</year>
            <month>Aug</month>
            <day>20</day>
            <volume>24</volume>
            <issue>4</issue>
            <fpage>200</fpage>
            <page-range>200-204</page-range>
            <pub-id pub-id-type="pmid">29269707</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mauermann</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Neurologic Complications of Lymphoma, Leukemia, and Paraproteinemias.</article-title>
            <source>Continuum (Minneap Minn)</source>
            <year>2017</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>3, Neurology of Systemic Disease</issue>
            <fpage>669</fpage>
            <page-range>669-690</page-range>
            <pub-id pub-id-type="pmid">28570324</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gultekin</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Voltz</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Eichen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Posner</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients.</article-title>
            <source>Brain</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>123 ( Pt 7)</volume>
            <fpage>1481</fpage>
            <page-range>1481-94</page-range>
            <pub-id pub-id-type="pmid">10869059</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kobaidze</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Harrison</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Burklin</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Patidar</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Riccardi</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>AUTOIMMUNE LIMBIC ENCEPHALITIS (CASE REPORTS).</article-title>
            <source>Georgian Med News</source>
            <year>2017</year>
            <month>May</month>
            <issue>266</issue>
            <fpage>69</fpage>
            <page-range>69-74</page-range>
            <pub-id pub-id-type="pmid">28628018</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Collao-Parra</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Romero-Urra</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Delgado-Derio</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>[Autoimmune encephalitis. A review].</article-title>
            <source>Rev Med Chil</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>146</volume>
            <issue>3</issue>
            <fpage>351</fpage>
            <page-range>351-361</page-range>
            <pub-id pub-id-type="pmid">29999106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Said</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Reyna</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Alkhateeb</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Diaz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nahleh</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis, an uncommon presentation of a common cancer: Case report and discussion.</article-title>
            <source>Am J Case Rep</source>
            <year>2013</year>
            <volume>14</volume>
            <fpage>391</fpage>
            <page-range>391-4</page-range>
            <pub-id pub-id-type="pmid">24116265</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Antibody-Mediated Encephalitis.</article-title>
            <source>N Engl J Med</source>
            <year>2018</year>
            <month>Mar</month>
            <day>01</day>
            <volume>378</volume>
            <issue>9</issue>
            <fpage>840</fpage>
            <page-range>840-851</page-range>
            <pub-id pub-id-type="pmid">29490181</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Geis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Graus</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System.</article-title>
            <source>Physiol Rev</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>97</volume>
            <issue>2</issue>
            <fpage>839</fpage>
            <page-range>839-887</page-range>
            <pub-id pub-id-type="pmid">28298428</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ando</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Goto</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Mano</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nomura</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Kurashige</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mimuro</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Iwasaki</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Katsuno</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Yoshida</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic autoimmune encephalitis associated with pleomorphic lung carcinoma: An autopsy case report.</article-title>
            <source>Neuropathology</source>
            <year>2018</year>
            <month>May</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">29781194</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>H&#x000f6;ftberger</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lassmann</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Immune-mediated disorders.</article-title>
            <source>Handb Clin Neurol</source>
            <year>2017</year>
            <volume>145</volume>
            <fpage>285</fpage>
            <page-range>285-299</page-range>
            <pub-id pub-id-type="pmid">28987176</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pollak</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Lennox</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Benros</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Tebartz van Elst</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Steiner</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Frodl</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bogerts</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Tian</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Groc</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Baune</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Endres</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Haroon</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Yolken</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Benedetti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Halaris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Stassen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Leboyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Otto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Vincent</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Najjar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bechter</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin.</article-title>
            <source>Lancet Psychiatry</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>93</fpage>
            <page-range>93-108</page-range>
            <pub-id pub-id-type="pmid">31669058</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nathoo</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Anderson</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Jirsch</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Extreme Delta Brush in Anti-NMDAR Encephalitis Correlates With Poor Functional Outcome and Death.</article-title>
            <source>Front Neurol</source>
            <year>2021</year>
            <volume>12</volume>
            <fpage>686521</fpage>
            <pub-id pub-id-type="pmid">34305794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Long-Term Memory Dysfunction in Limbic Encephalitis.</article-title>
            <source>Front Neurol</source>
            <year>2019</year>
            <volume>10</volume>
            <fpage>330</fpage>
            <pub-id pub-id-type="pmid">31080433</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Blattner</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>de Bruin</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Bucelli</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>Day</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Sleep disturbances are common in patients with autoimmune encephalitis.</article-title>
            <source>J Neurol</source>
            <year>2019</year>
            <month>Apr</month>
            <volume>266</volume>
            <issue>4</issue>
            <fpage>1007</fpage>
            <page-range>1007-1015</page-range>
            <pub-id pub-id-type="pmid">30741377</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hao</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lv</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Coexistence of Lambert-Eaton myasthenic syndrome and autoimmune encephalitis with anti-CRMP5/CV2 and anti-GABAB receptor antibodies in small cell lung cancer: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>May</month>
            <volume>97</volume>
            <issue>19</issue>
            <fpage>e0696</fpage>
            <pub-id pub-id-type="pmid">29742721</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pastuszak</surname>
                <given-names>&#x0017b;</given-names>
              </name>
              <name>
                <surname>St&#x00119;pie&#x00144;</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tomczykiewicz</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Piusi&#x00144;ska-Macoch</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kordowska</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Galbarczyk</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>&#x0015a;wistak</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Limbic encephalitis - a&#x000a0;report of four cases.</article-title>
            <source>Cent Eur J Immunol</source>
            <year>2017</year>
            <volume>42</volume>
            <issue>2</issue>
            <fpage>213</fpage>
            <page-range>213-217</page-range>
            <pub-id pub-id-type="pmid">28860940</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tsunoda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kiwamoto</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Homma</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yabuuchi</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kitazawa</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Shiozawa</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Nakazawa</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hosaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Ishii</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tamaoka</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hizawa</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis with late-onset magnetic resonance imaging findings: A case report.</article-title>
            <source>Mol Clin Oncol</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>7</volume>
            <issue>2</issue>
            <fpage>259</fpage>
            <page-range>259-262</page-range>
            <pub-id pub-id-type="pmid">28781798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nagafuji</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yokoi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Fujiwara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sato</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Saito</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis associated with mixed olfactory neuroblastoma and craniopharyngioma: A case report and literature review.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Jun</month>
            <volume>97</volume>
            <issue>24</issue>
            <fpage>e10932</fpage>
            <pub-id pub-id-type="pmid">29901583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rao</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Chipinapi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bharadwaj</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kissell</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>An unusual case of altered mental status in a young woman.</article-title>
            <source>N Am J Med Sci</source>
            <year>2011</year>
            <month>Nov</month>
            <volume>3</volume>
            <issue>11</issue>
            <fpage>518</fpage>
            <page-range>518-9</page-range>
            <pub-id pub-id-type="pmid">22361499</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schroeder</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Back</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Koc</surname>
                <given-names>&#x000dc;</given-names>
              </name>
              <name>
                <surname>Strassburger-Krogias</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Reinacher-Schick</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gold</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Haghikia</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Breakthrough treatment with bortezomib for a patient with anti-NMDAR encephalitis.</article-title>
            <source>Clin Neurol Neurosurg</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>172</volume>
            <fpage>24</fpage>
            <page-range>24-26</page-range>
            <pub-id pub-id-type="pmid">29960102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scheibe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pr&#x000fc;ss</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mengel</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kohler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>N&#x000fc;mann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>K&#x000f6;hnlein</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruprecht</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alexander</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hiepe</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Meisel</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Bortezomib for treatment of therapy-refractory anti-NMDA receptor encephalitis.</article-title>
            <source>Neurology</source>
            <year>2017</year>
            <month>Jan</month>
            <day>24</day>
            <volume>88</volume>
            <issue>4</issue>
            <fpage>366</fpage>
            <page-range>366-370</page-range>
            <pub-id pub-id-type="pmid">28003505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;zkale</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Erol</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>&#x000d6;zkale</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kozano&#x0011f;lu</surname>
                <given-names>&#x00130;</given-names>
              </name>
            </person-group>
            <article-title>Overview of therapeutic plasma exchange in pediatric neurology: a single-center experience.</article-title>
            <source>Acta Neurol Belg</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>118</volume>
            <issue>3</issue>
            <fpage>451</fpage>
            <page-range>451-458</page-range>
            <pub-id pub-id-type="pmid">29882008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Y&#x000fc;cesan</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arslan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Arat</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Y&#x000fc;cemen</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ayyildiz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ilhan</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Mutluer</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Therapeutic plasma exchange in the treatment of neuroimmunologic disorders: review of 50 cases.</article-title>
            <source>Transfus Apher Sci</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>103</fpage>
            <page-range>103-7</page-range>
            <pub-id pub-id-type="pmid">17224307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Meng</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Najjar</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lado</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Najjar</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune Encephalitis: A Physician's Guide to the Clinical Spectrum Diagnosis and Management.</article-title>
            <source>Brain Sci</source>
            <year>2022</year>
            <month>Aug</month>
            <day>25</day>
            <volume>12</volume>
            <issue>9</issue>
            <pub-id pub-id-type="pmid">36138865</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Armangue</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Leypoldt</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Dalmau</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Autoimmune encephalitis as differential diagnosis of infectious encephalitis.</article-title>
            <source>Curr Opin Neurol</source>
            <year>2014</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>3</issue>
            <fpage>361</fpage>
            <page-range>361-8</page-range>
            <pub-id pub-id-type="pmid">24792345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Attademo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>De Falco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rosanova</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Esposito</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mazio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Foschini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Santaniello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fiore</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Matano</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Manganelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Carlomagno</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A case report of limbic encephalitis in a metastatic colon cancer patient during first-line bevacizumab-combined chemotherapy.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>97</volume>
            <issue>9</issue>
            <fpage>e0011</fpage>
            <pub-id pub-id-type="pmid">29489644</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shimoyama</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Umegaki</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Agui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kadono</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Minami</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Anti-NMDA receptor encephalitis presenting as an acute psychotic episode misdiagnosed as dissociative disorder: a case report.</article-title>
            <source>JA Clin Rep</source>
            <year>2016</year>
            <volume>2</volume>
            <issue>1</issue>
            <fpage>22</fpage>
            <pub-id pub-id-type="pmid">29497677</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shen</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Guan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis associated with lung cancer.</article-title>
            <source>Sci Rep</source>
            <year>2018</year>
            <month>May</month>
            <day>01</day>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>6792</fpage>
            <pub-id pub-id-type="pmid">29717222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inuzuka</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>[Limbic encephalitis: etiology, pathogenesis, diagnosis and therapy].</article-title>
            <source>Rinsho Shinkeigaku</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>44</volume>
            <issue>11</issue>
            <fpage>799</fpage>
            <page-range>799-801</page-range>
            <pub-id pub-id-type="pmid">15651295</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bloch</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Hwang</surname>
                <given-names>WC</given-names>
              </name>
              <name>
                <surname>Baehring</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Chambers</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>Paraneoplastic limbic encephalitis: ovarian cancer presenting as an amnesic syndrome.</article-title>
            <source>Obstet Gynecol</source>
            <year>2004</year>
            <month>Nov</month>
            <volume>104</volume>
            <issue>5 Pt 2</issue>
            <fpage>1174</fpage>
            <page-range>1174-7</page-range>
            <pub-id pub-id-type="pmid">15516442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Herman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Zsigmond</surname>
                <given-names>IR</given-names>
              </name>
              <name>
                <surname>Peter</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Rethelyi</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>[Review of the psychiatric aspects of anti-NMDA (N-methyl-D-aspartic acid) receptor encephalitis, case report, and our plans for a future study].</article-title>
            <source>Neuropsychopharmacol Hung</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>4</issue>
            <fpage>199</fpage>
            <page-range>199-208</page-range>
            <pub-id pub-id-type="pmid">28259863</pub-id>
          </element-citation>
        </ref>
        <ref id="article-26632.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Altena</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Wijnberg</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Kolwijck</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>de Hullu</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Massuger</surname>
                <given-names>LF</given-names>
              </name>
            </person-group>
            <article-title>A patient with bilateral immature ovarian teratoma presenting with paraneoplastic encephalitis.</article-title>
            <source>Gynecol Oncol</source>
            <year>2008</year>
            <month>Feb</month>
            <volume>108</volume>
            <issue>2</issue>
            <fpage>445</fpage>
            <page-range>445-8</page-range>
            <pub-id pub-id-type="pmid">18029289</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
